Skip to main content
. 2018 Apr 16;18(9):2274–2284. doi: 10.1111/ajt.14709

Table 1.

Patient, donor, and transplant characteristics

Characteristics No DSAs (n = 4157) DSAs (n = 567) P‐value Total cohort (N = 4724)
Patient
Age at transplant, y, mean ± SD 45.6 ± 14.4 44.2 ± 13.9 .01a 45.4 ± 14.4
Female sex, n 1561 (37.6) 333 (58.7) <.001b 1894 (40.1)
PRA at time of transplant, %, mean ± SD 3.5 ± 12.9 24.4 ± 30.7 <.001a 6.0 ±17.5
Highest PRA, %, mean ± SD 9.8 ± 21.0 43.6 ± 36.3 <.001a 13.8 ± 25.8
Dialysis .0004b
No, n (%) 472 (1.4) 43 (7.6) 515 (10.9)
Yes—hemodialysis, n 2140 (51.4) 332 (58.6) 2472 (52.3 )
Yes—peritoneal dialysis, n 1529 (36.8) 186 (32.8) 1715 (36.3)
Unknown, n (%) 16 (0.4) 6 (1.1) 22 (0.5)
Time on dialysis, y, mean ± SD 2.7 ± 2.4 3.4 ± 3.0 <.0001a 2.8 ± 2.5
Donor
Donor age, y, mean ± SD 44.4 ± 14.9 44.0 ± 15.8 1.00a 44.4 ± 15.0
Donor female sex, n 2128 (51.2) 258 (45.5) .01b 2386 (50.5)
Type of donor <.001b
Living, n 1350 (32.5) 137 (24.2) 1487 (31.4)
Deceased—DBD, n 2076 (49.9) 351 (61.9) 2427 (51.4)
Deceased—DCD, n (%) 731 (17.6) 79 (13.9) 810 (17.2)
Cold ischemia time
Deceased donors, h, mean ± SD 21.7 ± 7.3 22.8 ± 6.8 .001a 21.9 ± 7.2
Living donors, h, mean ± SD 2.5 ± 1.6 2.5 ± 1.0 .53 a 2.5 ± 1.5
Transplant
Retransplant, n (%) 453 (10.9) 270 (47.6) <.001b 723 (15.3)
HLA‐A/B/DR broad mismatches, mean ± SD 2.3 ± 1.5 2.4 ± 1.3 .15a 2.4 ± 1.5
Induction therapy
IL‐2 receptor blocker, n (%)  913 (21.9) 109 (19.2) .14b 1022 (21.6)
T cell–depleting antibody,cn (%) 145 (3.6) 39 (6.9) <.001b 184 (3.9)
Initial immunosuppression, n (%)
Steroids 4069 (97.9) 547 (96.5) .04b 4616 (97.7)
MMF/azathioprine 3163 (76.1) 442 (78) .20b 3605 (76.3)
Cyclosporine/tacrolimus 3892 (93.6) 542 (95.6) .07b 4434 (93.9)
Sirolimus 260 (6.3) 26 (4.6) .12b 286 (6.1) 
Other 555 (13.4) 53 (9.4) .008b 608 (12.9)
Unknown 14 (0.3) 3 (0.5) .47b 17 (0.4)

DBD, donation after brain death; DCD, donation after cardiac death; DSA, donor‐specific HLA antibody; IL, interleukin; MMF, mycophenolate mofetil.

a

Mann–Whitney U test for continuous variables.

b

χ2 test for categorical variables.

c

T cell–depleting antibody therapy: ALG, ATG, OKT3 monoclonal antibodies.